Autolus Therapeutics Reports Positive Phase 1 CARLYSLE Trial Data for Obe-cel in Severe Refractory Lupus
I'm PortAI, I can summarize articles.
Autolus Therapeutics announced positive preliminary results from its Phase 1 CARLYSLE trial for obe-cel in severe refractory lupus. The trial showed deep B-cell depletion and durable responses, with no severe safety issues reported. Following these results, Autolus has initiated the LUMINA Phase 2 trial for lupus nephritis. The findings were presented at the 2025 ASH Annual Meeting.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments